Drug Pricing and Reimbursement: Case for Decentralization

Decentralization has not yet been applied within the cryptic act of drug pricing. The key advances of decentralization in supply chains and clinical trials prove promising. Consensus reaching is crucial. Stakeholders are unlikely to favor transparency as that is the method by which they can fulfill their fiduciary responsibility in maximizing profits for companies. Therefore, without government intervention through stringent policy, stakeholders will not easily give up on rising profit margins

Comments Off on Drug Pricing and Reimbursement: Case for Decentralization